Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arvinas and Bayer to use PROTAC technology in cardiology, gynecology, and oncology

Executive Summary

Arvinas Inc. and Bayer AG agreed to use the former’s PROTAC technology to develop drug candidates for cardiovascular and gynecological diseases, and cancer. Separately, the companies established a 50/50 joint venture that will use PROTAC in the agricultural industry.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies